

# Isa Mambetsariev

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8561080/publications.pdf>

Version: 2024-02-01

43  
papers

692  
citations

687363

13  
h-index

610901

24  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1075  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends in Molecular Medicine, 2020, 26, 119-134.	6.7	121
2	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2021, 2, 100186.	6.5	90
3	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. Journal of Thoracic Oncology, 2021, 16, 1030-1041.	1.1	79
4	Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magnetic Resonance Imaging, 2020, 69, 49-56.	1.8	34
5	Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. Oncotarget, 2018, 9, 19793-19806.	1.8	34
6	Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. Journal of Thoracic Disease, 2020, 12, 5086-5095.	1.4	29
7	A Non-genetic Mechanism Involving the Integrin $\alpha 24$ /Paxillin Axis Contributes to Chemoresistance in Lung Cancer. IScience, 2020, 23, 101496.	4.1	27
8	Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Journal of Clinical Medicine, 2019, 8, 1726.	2.4	26
9	Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. Frontiers in Oncology, 2020, 10, 593.	2.8	25
10	Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 621088.	2.8	23
11	MET receptor in oncology: From biomarker to therapeutic target. Advances in Cancer Research, 2020, 147, 259-301.	5.0	20
12	EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis, 2019, 8, 49.	4.9	17
13	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine, 2020, 9, 1870.	2.4	16
14	Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. Oncotarget, 2018, 9, 26226-26242.	1.8	14
15	Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget, 2017, 8, 26414-26423.	1.8	12
16	Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2022, 11, 1429.	2.4	12
17	Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. IScience, 2020, 23, 101692.	4.1	9
18	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers, 2021, 13, 2776.	3.7	9

#	ARTICLE	IF	CITATIONS
19	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1820-1835.	4.1	9
20	Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. <i>Journal of Clinical Medicine</i> , 2019, 8, 1038.	2.4	8
21	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	2.0	8
22	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e257-e265.	2.9	8
23	Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005785.	1.2	8
24	Value-Based Medicine and Integration of Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 833-840.	3.8	7
25	Precision medicine and actionable alterations in lung cancer: A single institution experience. <i>PLoS ONE</i> , 2020, 15, e0228188.	2.5	7
26	Effective osimertinib treatment in a patient with discordant T790M mutation detection between liquid biopsy and tissue biopsy. <i>BMC Cancer</i> , 2018, 18, 314.	2.6	6
27	The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 1897-1908.	2.4	5
28	Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 1723.	2.4	5
29	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting – Role of Academic and Hybrid Modeling. <i>Journal of Clinical Medicine</i> , 2020, 9, 1884.	2.4	5
30	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. <i>Clinical Lung Cancer</i> , 2021, 22, e703-e707.	2.6	5
31	Heuristic value-based framework for lung cancer decision-making. <i>Oncotarget</i> , 2018, 9, 29877-29891.	1.8	5
32	Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e16266.	0.5	4
33	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	3.7	2
34	Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 568.	2.6	1
35	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	1.9	1
36	Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. <i>International Journal of Oncology</i> , 2020, 57, 80-86.	3.3	1

#	ARTICLE	IF	CITATIONS
37	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. <i>Journal of Thoracic Disease</i> , 2020, 12, 5096-5103.	1.4	0
38	Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?. <i>JCO Oncology Practice</i> , 2021, 17, 52-53.	2.9	0
39	Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Non-Small Cell Lung Cancer and Malignant Mesothelioma. <i>FASEB Journal</i> , 2018, 32, 835.9.	0.5	0
40	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
41	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
42	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
43	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0